## 

## 

## 

|||||||Page|
|---|---|---|---|---|---|---|
|Legal and administrative||information|||||
|Message from|our Chairman||||||
|Report ofthe|Trustees||||||
|Report ofthe|independent||Auditors|||19|
|Consolidated|statement|of|financial|activities||23|
|(incorporating|statutory|income &||expenditure|account)||
|Consolidated|balance sheet|||||24|
|Charity balance sheet||||||26|
|Consolidated|cash flow|statement||and note||28|
|Notes to the|financial<br>statements|||||29|





## 

|LEGAL AND ADMINISTRATIVE<br>INFORMATION|LEGAL AND ADMINISTRATIVE<br>INFORMATION|LEGAL AND ADMINISTRATIVE<br>INFORMATION|LEGAL AND ADMINISTRATIVE<br>INFORMATION|LEGAL AND ADMINISTRATIVE<br>INFORMATION|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|President<br>Mr Richard Helmsley||||MA FCA|||||||||
|Vice Presidents<br>Cllr Brian||Cleasby||||Patrons|||Mr John|Bill|||
|Mr Fabian||Hamilton|MP||||||Mrs Anne||Bill||
|Prof Shervanthi<br>Homer-Vanniasinkam|||||||||Chnstopher|||Kane|
|IBSc,MBBS, FRCSE, FRCS|||||||||Tammy|Kane|||
||||||||||Mark Bonnar||||
||||||||||Paul Insect||||
||||||||||Robert Smith||||
|Past Presidents<br>Mr David||A Watson MBE FRCS|||||||||||
|Mr Keith||Louden OBE|||||||||||
|Trustees|||||||||||||
|Chairman|||||Vice Chairman||||||||
|Mr Paul Rogerson<br>CBE DL|||||Ms Julie|Fenwick MSc|||||||
|Mr Pierre Bouvet LLB|||||||||||||
|Mr Peter C Braidley MBBS|FRCS (Eng) FRCS (CTh)||||||||||||
|Mr James Breeze B.Sc.(Hans.||) DipM ACIM|||||||||||
|Mr Richard J Brown FCA|||||||||||||
|Dr Catherine<br>J Dickinson<br>MA||PhD FRCP|||||||||||
|Dr David<br>F Dickinson<br>MB ChB DCH FRCP|||||||||||||
|Mr Anthony<br>D Knight|||||||||||||
|Mrs Linda lylundoza<br>CIPD (from 20 October 2021)|||||||||||||
|Prof Christopher<br>Newman|MA PhD FRCP||||||||||||
|Mr Kevin GWatterson<br>MB|BSFRACS||||||||||||
|Mr Richard<br>C Hemsley<br>MA|FCA (retired||24June 2021)||||||||||
|Mr Anthony<br>R Kilner LLB (retired 24June||||2021)|||||||||
|Mr Paul Smith FCSI (retired|7 March 2022)||||||||||||
|Principal Officers:|||||||||||||
|Ms Kate Bratt-Farrar|||||Chief Executive|||Officer|||||
|Dr Phil Newby<br>BSc (Hons) MSc PhD|||||Head of Finance|||(Company||Secretary)|||
|Registered Ofgce &Head|Offic:||||Regional office:||||||||
|Suite 12D|||||13St Paul's Square||||||||
|Joseph's Well|||||Birmingham||||||||
|Leeds LS3 1AB|||||831RB||||||||
|Teh 01132347474|||||Teh 0121454||1799||||||
|Email: info@heartresearch.||org.uk|||Email: midlands@heartresearch.|||||||org.uk|
|Independent<br>Auditors:|||||Stockbrokers||and||Investment|||Managers:|
|BHP LLP|||||J M Finn &Co||Ltd||||||
|1st Floor Mayesbrook<br>House|||||4Coleman Street||||||||
|Lawnswood<br>Business Park|||||London||||||||
|Leeds<br>LS166QY|||||EC2R STA||||||||
|Bankers:|||||Solicitors.||||||||
|Barclays Bank PLC|||||Walker|Morris||LLP|||||
|Barclays Business Centre|||||Kings Court||||||||
|Albion Street|||||12King|Street|||||||
|Leeds LS1 1PA|||||Leeds LS12HL||||||||





## 

## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 



## 

## 

## 

## 

## 



## 

## 

## 

## 



## 

## 

## 

## 

## 



## 

## 

## 

## 

## 



## 

## 

## 


## 

## 

## 

## 



## 

## 

## 



## 

## 

## 

## 



## 

## 

## 

## 

## 

## 

## 

## 



## 

## 

## 

## 



## 

## 

## 

## 

## 

## 

## 

## 



## 

## 

## 

## 



## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 

## 



## 

## 

## 



## 

## 

## 

## 

## 



## 

## 

## 

## 

## 



## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 



## 

## 

## 



## 

## 

## 

|||||Unrestricted|Restricted|Total|Total|
|---|---|---|---|---|---|---|---|
|||||funds|funds|funds|funds|
|||||2021|2021|2021|2020|
||||Note|6|6|6|E|
|income from:||||||||
|Donations and legacies||||2,256,447|74,809|2,331,256|2,448,853|
|Sponsored events||||58,666|32,261|90,927|121,664|
|Trading subsidiary||||144,061||144,061|1,604|
|investments||||164,837||164,837|171,316|
|Total income||||2,624,011|107,070|2,731,081|2,743,437|
|Expenditure<br>on:||||||||
|Raising funds|||6|468,042|4,968|473,010|422,390|
|Charitable<br>activities|||7|2,937,924|166,643|3,104,567|1,166,799|
|Totalexpenditure||||3,405,966|171,611|3,577,577|1,589,189|
|Net (expenditure)/income||before net||||||
|gains on investments||||(781,955)|(64,541)|(846,496)|1,154,248|
|Net gains on investments||||759,564||759,564|279,169|
|Net (expenditure)/income||||(22,391)|(64,541)|(86,932)|1,433,417|
|Transfers between|funds||21|6,506|(6,506)|||
|Net movement<br>In funds||||(15,885)|(71,047)|(86,932)|1,433,417|
|Reconciliation offunds:||||||||
|Total funds brought|forward|||6,691,748|221,617|6,913,365|5479 948|
|Net movement<br>in funds||||(15,885)|(71,047)|(86,932)|1,433,417|
|Total funds carried|forward|||6,675,863|150,570|6,826,433|6,913,365|









## 










## 

## 

|||||2021|2020|
|---|---|---|---|---|---|
||||Note|6|6|
|Cash flows from operating<br>activities||||||
|Net cash generated<br>by operating<br>activities|||24|1,384,050|150,186|
|Cash flows from investing<br>activities||||||
|Movement<br>in investment<br>broker cash||||(256,091)|(135,931)|
|Dividends<br>and interest received||||154,257|165,194|
|Purchase ofintangible<br>assets||||(1,068)||
|Proceeds from 's'ale ofinvestments||||488,303|1,374,507|
|Purchase ofinvestments||||(1,366,134)|(1,188,048)|
|Net cash (used in)/provided<br>by investing||activities||(980,733)|215,722|
|Change<br>in cash and cash equivalents|in the year|||403,317|365,908|
|Cash and cash equivalents<br>at the beginning||ofthe year||1,815,824|1,449,916|
|Cash and cash equivalents<br>atthe end|ofthe year||25|2,219,141|1,815,824|





## 

## 

## 

## 

## 



## 

## 



## 

## 

## 

## 

## 

## 

## 





## 



## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

|||Unrestricted|Restricted|Total|Tota I|
|---|---|---|---|---|---|
|||funds|funds|funds|funds|
|||2021f|2021<br>f|2021<br>f|2020f|
|Donations||248,273|73,309|321,582|285,159|
|Legacies||2,008,174|1,500|2,009,674|2,107,266|
|Coronavirus|Job Retention Scheme Grant||||56,428|
|Total 2021||2,256,447|74,809|2,331,256|2,448,853|
|Total 2020||2,341,470|107,383|2,448,853||
|Investment|income|||||
||||Unrestricted|Total|Total|
||||funds|funds|funds|
||||2021f|2021<br>f|2020f|
|Income from|fixed asset investments||148,498|148,498|122,588|
|Income from|current asset investments||5,759|5,759|42,606|
|Bank and other interest|||10,580|10,580|6,122|
|Total 2021|||164,837|164,837|171,316|
|Total 2020|||171,316|171,316||



## 



## 

## 

## 

## 

||||Unrestricted|Restricted|Total|Total|
|---|---|---|---|---|---|---|
||||funds|funds|funds|funds|
||||2021|2021|2021|2020|
||||E|6||E|
|Postage|||8,889|116|9,005|5,634|
|Advertising|publicity &|event costs|||||
|Legacy related|||840||&40|5,050|
|Event related|||6,235|3,800|10,035|28,252|
|General|||7,033|975|8,008|9,824|
|Other fundra|ising costs||8,341|77|8,418|7,471|
|tegrrl and professional|||||||
|Legacy related|||5,190||5,190|2,919|
|Investment|management|costs|57,783||57,783|51,947|
|Apportioned|support costs:||||||
|Operating<br>lease rentals|||27,284||27,284|13,897|
|Other premises costs|||11,516||11,516|6,230|
|Telephone|||2,645||2,645|1,184|
|Training|||8,670||8,670|2,097|
|Information|technology||27,739||27,739|15,511|
|Marketing|||18,393||18,393|23,758|
|Othercosts|||20,345||20,345|31,217|
|Wages and|salaries||217,601||217,601|184,999|
|Social security costs|||18,971||18,971|16,576|
|Pension costs|||20,567||20,567|15,824|
|Total2021|||468,042|4,968|473,010|422,390|
|Total 2020|||421,845|545|422,390||





## 

||||Unrestricted|Restricted|Total|Tota I|
|---|---|---|---|---|---|---|
||||funds|funds|funds|funds|
||||2021|2021|2021|2020|
||||6|6|6|f|
|Grants|||||||
|Medical research grants awarded|||1,999,856|36,749|2,036,605|293,551|
|Grants awarded||in previous years no longer|||||
|required|||(8,360)||(8,360)|(112,349)|
|Healthy<br>Hearts||grants awarded||118,451|118,451||
|Grants awarded||in previous years no longer|||||
|required|||(1,772)|(1,425)|(3,197)|(8,443)|
|Direct support||costs|||||
|Medical research|||71,124|11,026|82,150|27,371|
|Prevention|and|education|54,394|790|55,184|185,982|
|Prevention|and|education -staff costs|197,397||197,397|36,430|
|Trading<br>corn|pa|ny|72,569||72,569|6,898|
|Dissemination||ofinformation|||||
|Production|of 'Pulse'||2,345||2,345||
|Web-site maintenance|||2,826|30|2,856|3,358|
|Apporterned|support costs:||||||
|Staff costs|||327,853||327,853|506,535|
|Operating<br>lease rentals|||34,787||34,787|32,379|
|Other premises||costs|14,683||14,683|14,516|
|Telephone|||3,373||3,373|2,761|
|Training|||10,975|79|11,054|4,887|
|information|technology||24,001||24,001|13,421|
|Marketing|||15,831|85|15,916|20,556|
|Other costs|||17,203|858|18,061|27,011|
|Governance|costs (note 8)||98,839||98,839|111,935|
|Total 2021|||2,937,924|166,643|3,104,567|1,166,799|
|Total 2020|||1,132,923|33,876|1,166,799||





## 

## 

|||||Unrestricted|Total|Total|
|---|---|---|---|---|---|---|
|||||funds|funds|funds|
|||||2021|2021|2020|
|||||8|6|E|
|Auditor's<br>remuneration||||14,033|14,033|11,640|
|Legal, professional||and consultancy|fees|2,444|2,444|3,583|
|Trustee indemnity||insurance||529|529|529|
|Trustee meeting expenses||||272|272|154|
|Other governance||costs||1,654|1,654||
|Apportioned|support costs||||||
|Staff costs||||57,856|57,856|76,461|
|Operating<br>lease rentals||||6,139|6,139|4,888|
|Other premises costs||||2,591|2,591|2,191|
|Telephone||||595|595|417|
|Training||||1,951|1,951|738|
|lnfomation|technology|||4,461|4,461|2,494|
|Marketing||||2,958|2,958|3,820|
|Other costs||||3,356|3,356|5,020|
|Total 2021||||98,839|98,839|111,935|
|Total 2020||||111,935|111,935||





## 

## 

## 

||||||Total|Total|
|---|---|---|---|---|---|---|
|||Staff costs|Depreciation|Other costs|funds|funds|
|||||||2020|
||||6|8||f|
|Raising funds||257,139|1,027|214,844|473,010|422,390|
|Charitable|activities|583,106|1,054|2 520 407|3,104,567|1,166,799|
|Total 2021||840,245|2,081|2,735,251|3,577,577|1,589,189|
|Total 2020||836,825|4,216|748,148|1,589,189||





## 

## 

## 

||||||Charitable||Total|Total|
|---|---|---|---|---|---|---|---|---|
|||||Raising funds|activities|Governance|funds|funds|
|||||||||2020|
|||||||||6|
|Staff costs||||257,139|327,853|57,856|642,848|800,395|
|Premises (including<br>rates)||rent|and|38,800|49,470|8,730|97,000|74,101|
|Telephone||||2,645|3,373|595|6,613|4,362|
|Training||||8,670|11,054|1,951|21,675|7,722|
|lnfomation<br>technology<br>depreciation)|||(including|27,739|24,001|4,461|56,201|31,426|
|Marketing||||18,393|15,916|2,958|37,267|48,134|
|Other costs||||20,345|18,061|3,356|41,762|63,248|
|Total 2021||||373,731|449,728|79,907|903,366|1,029,388|
|Total 2020||||311,293|622,066|96,029|1,029,388||





## 

## 

## 

||||||Group||Group|Group|Charity|Charity|
|---|---|---|---|---|---|---|---|---|---|---|
||||||2021|||2020|2021|2020|
||||||g||||6|6|
|Wages and salaries|||||717,181||712,664||717,181|712,664|
|Social security|costs||||63,297||64,175||63,297|64,175|
|Contribution|to defined contdibution||pension||||||||
|schemes|||||59,767||59,986||59,767|59,986|
||||||840,245||836,825||840,245|836,825|
|The average number ofpersons employed||||by the charity|during the|year|was|as follows:|||
||||||||||Group|GI'0 up|
||||||||||2021|2020|
||||||||||No.|No.|
|Administration,|management,|fundraising||and charitable|expenditure|support|||27|26|
|The number ofemployees whose employee||||benefits (excluding<br>employer|||pension costs)||exceeded f60000was:||
||||||||||Group|Group|
||||||||||2021|2020|
||||||||||No.|No.|
|ln the band 660,001 - 670,000|||||||||1|1|





## 

## 

## 

|12.|Intangible<br>assets|||
|---|---|---|---|
||Group|||
||||App|
||||Development|
||||E|
||Cost|||
||At 1January 2021||50,000|
||At 31December 2021||50,000|
||Amortlsatl on|||
||Charge for the year||50,000|
||At 31December 2021||50,000|
||Net book value|||
||At 31December 2021|||
||At 31December 2020||50,000|
||The charity has Enil intangible|fixed assets (2020:Enil).||





## 

## 

## 

|13.|Tangible fixed assets||
|---|---|---|
||Group||
|||Office|
|||equipment|
|||6|
||Costor valuation||
||At 1January 2021|&8/31|
||Additions|1,068|
||At 31December 2021|89,499|
||Depreciation||
||At 1January 2021|84,268|
||Charge for the year|2,081|
||At 31December 2021|86,349|
||Net book value||
||At 31December 2021|3,150|
||At 31December 2020|4,163|





## 

## 

## 

## 

|Charity||
|---|---|
||Office|
||equipment|
||6|
|Cost or valuation||
|At 1January 2021|88,169|
|Additions|1,068|
|At 31December 2021|89,237|
|Depreciation||
|At 1January 2021|84,006|
|Charge for the year|2,081|
|At 31December 2021|86,087|
|Net book value||
|At31December 2021|3,150|
|At 31December 2020|4,163|





## 

## 

## 

## 

||||Quoted|Total|Total|
|---|---|---|---|---|---|
||||investments|funds|funds|
||||2021f|2021f|2020f|
|Group||||||
|Market value||||||
|At 1January<br>2020|||5,709,810|5,709,810|5,456,770|
|Additions at cost|||1,416,116|1,416,116|1,188,048|
|Disposal proceeds|||(448,303)|(448,303)|(1,374,507)|
|Net realised and unrealised|gains/ (losses)||696,241|696,241|439,499|
|At31December 2021|||7,373,864|7,373,864|5,709,810|
|Cash awaiting<br>reinvestment|||385,387|385,387|127,840|
||||7,759,251|7,759,251|5,837,650|
|||Quoted|Investment<br>in|Total|Total|
|||investments|subsidiary|funds|funds|
|||2021<br>f|2021<br>f|2021f|2020<br>f|
|Company||||||
|Market value/cost||||||
|At 1January 2020||5,709,810|100|5,709,910|5,456,870|
|Additions at cost||1,416,116||1,416,116|1,188,048|
|Disposal proceeds||(448,303)||(448,303)|(1,374,507)|
|Net realised and unrea lised|gains/ (losses)|696,241||696,241|439,499|
|At31December 2021||7,373,864||7,373,964|5,709,910|
|Cash awaiting<br>reinvestment||385,387||385,387|127,840|
|||7,759,251|100|7,759,351|5,837,750|





## 

## 

## 



## 

## 

## 

## 

## 

||||Group|Group|
|---|---|---|---|---|
||||2021|2020|
||||E|E|
|Finished goods|||6,754|7,348|
|The chadty held no stock at the year end (2020:fNIL)|||||
|Debtors|||||
||Group|Group|Charity|Charity|
||2021<br>f|2020<br>F.|2021<br>f|2020f|
|Due after more than one year|||||
|Amounts<br>owed by group undertakings||||46,000|
|||||46,000|
|Due within one year|||||
|Trade debtors|||100||
|Amounts<br>owed by group undertakings|||84,239|37,344|
|Otherdebtors|1,606|854|1,293|854|
|Prepayments<br>and accrued income|95,442|66,986|95,442|66,986|
|Legacies receivable|1,106,827|1,496,808|1,106,827|1,496,808|
||1,203,975|1,564,648|1,287,901|1,647,992|



## 

## 

|||Group|Group|Charity|Charity|
|---|---|---|---|---|---|
|||2021f|2020f|2021f|2020f|
|Listed|investments||1,119,820||1,119,820|





## 

|18.|Creditors: Amounts<br>falling due|Creditors: Amounts<br>falling due|within one year|within one year||||
|---|---|---|---|---|---|---|---|
|||||Group|Group|Charity|Charity|
|||||2021f|2020f|2021f|2020<br>f|
||Trade creditors|||21,623|44,268|21,623|44,268|
||Other creditors|||4,267|2,750|4,267|2,742|
||Accruals and deferred|income||32,680|25,798|30,070|24,643|
||Grants accrued (see note 20)|||3,034,947|2,325,992|3,034,947|2,325,992|
|||||3,093,517|2,398,808|3,090,907|2,397,645|
|19.|Creditors: Amounts<br>falling due||after more than one year|||||
|||||Group|Group|Charity|Charity|
|||||2021|2020f|2021<br>f|2020<br>f|
||Grants accrued (see|note 20)||1,272,321|1,087,280|1,272,321|1,087,280|
|20.|Reconciliation<br>ofgrants accrued|||||||
|||||||2021|2020|
|||||||f|f|
||Opening<br>liability obligation|||||3,413,812|4,179,228|
||Medicalresearch<br>grants awarded|||in year||2,036,605|293,551|
||Healthy<br>Heart grants|awarded|in|the year||117,221||
||Provisions<br>no longer|required|by|grantees||(10,327)|(120,792)|
||Paid during the year|||||(1,250,043)|(938,175)|
||Closing liability obligation|||||4,307,268|3,413,812|





## 

## 

|21.|Statement offunds|||||||
|---|---|---|---|---|---|---|---|
||Statement offunds|- current year||||||
|||Balance at 1|||Transfers|Gains/|Balance at 31|
|||January 2021<br>6|Income<br>6|Expenditure<br>6|In/out<br>6|(Losses) <br>6|December 2021<br>6|
||Unrestricted|||||||
||funds|||||||
||Designated funds|||||||
||HRUK Heart|||||||
||Academy|19,054||(19,054)||||
||Translational|||||||
||Research|||||||
||Projects-|||||||
||Scotland|32,308||(32,308)||||
||Future Grants|||||||
||fund|3,754,253||(1,953,6801|||1,800,573|
|||3,805,615||(2,005,042)|||1,800,573|
||Genenrl funds|||||||
||General<br>Funds - all|||||||
||funds|2,886,133|2,624,011|(1,400,924)|6,506|759,564|4,875,290|
||Total Unrestricted|||||||
||funds|6,691,748|2,624,011|(3,405,966)|6,506|759,564|6,675,863|





## 

## 

## 

||Balance at 1||||Transfers|Gains/|Balance at31|
|---|---|---|---|---|---|---|---|
||ianuary 2021|income<br>f|Expenditure|f|in/out<br>f|(Lussesi<br>f|December 2021<br>f|
|Restricted funds||||||||
|Subways|158,658|17,678|(117,026)||||59,310|
|Heart Camps|20,498||||||20,498|
|The Mick Grainger||||||||
|In-Memory||||||||
|Masterclass|20,291|9,814|||||30,105|
|Aortic Arch||||||||
|Masterclass|12,042|13,499|(15,798)||||9,743|
|HOS / RESSCO-||||||||
|Scotland||36,749|(36,749)|||||
|PhO Studentship||||||||
|(Caravan<br>Guard)||18,614|||||18,614|
|Other|10,128|10,716|(2,038)||(6,506)||12,300|
||221,617|107,070|(171,611)||(6,506)||150,570|
|Totaloffunds|6,913,365|2,731,081|(3,577,577)|||759,564|6,826,433|





## 

## 

|21.|Statement of|funds|(continued)|||||||
|---|---|---|---|---|---|---|---|---|---|
||Statement of|funds|- prior year|||||||
||||Balance|at|||||Balance at|
||||13anuary||||Transfers|Gains/|31December|
||||2020||income|Expenditure|in/out|(Losses)|2020|
|||||E||6|E|6|6|
||Unrestricted|||||||||
||funds|||||||||
||Designated funds|||||||||
||HRUK Heart|||||||||
||Academy||163,654|||(144,600)|||19,054|
||Translational|||||||||
||Research|||||||||
||Projects-|||||||||
||Scotland||181,997|||(59,976)|(89,713)||32,308|
||Future Grants|||||||||
||fund||1,800,000|||(194,887)|2,149,140||3,754,253|
||||2,145,651|||(399,463)|2,059,427||3,805,615|
||General funds|||||||||
||General Funds|—all||||||||
||funds||3,158,661||2,629,103|(1,155,306)|(2,025,494)|279,169|2,886,133|
||Total Unrestricted|||||||||
||funds||5,304,312||2,629,103|(1,554,769)|33,933|279,169|6,691,748|





## 

## 

## 

||Balance at|||||Balance at|
|---|---|---|---|---|---|---|
||1january|||Transfers|Gains/|31December|
||2020<br>E|Income<br>E|Expenditure<br>E|in/out<br>E|(Losses)<br>f|2020<br>'f|
|Restricted funds|||||||
|Subwaya|125,434|26,426|6,798|||158,658|
|Heart Camps|20,498|||||20,498|
|The Mick Grainger|||||||
|In-Memory|||||||
|Masterclass|17,011|3,280||||20,291|
|Aortic Arch|||||||
|Masterclass|6,942|5,105|(5)|||12,042|
|Research-|||||||
|Scotland||35,855|(35,934)|79|||
|Other|5,751|43,668|(5,279)|(34,012)||10,128|
||175,636|114,334|(34,420)|(33,933)||221,617|
|Total offunds|5,479,948|2,743,437|(1,589,189)||279,169|6,913,365|





## 

## 



## 

## 

## 

|Summary|offunds|- current year||||||
|---|---|---|---|---|---|---|---|
|||Balance at 1|||Transfers|Gains/|Balance at 31|
|||January 1021<br>f|Incomef|Expendituref|in/outf|(Losses)<br>f|December 1011|
|Designated|funds|3,805,615||(2,005,042)|||1,800,573|
|General funds||2,886,133|2,624,011|(1,400,924)|6,506|759,564|4,875,290|
|Restricted|funds|221,617|107,070|(171,611)|(6,506)||150,570|
|||6,913,365|2,731,081|(3,577,577)||759,564|6,826,433|
|Summary|offunds|- prior year||||||
|||Balance at|||||Balance at|
|||1January|||Transfers|Gains/|31December|
|||2020<br>f|Income<br>f|Expenditure<br>f|in/outf|(Losses)<br>E|2020<br>f|
|Designated|funds|2,145,651||(399,463)|2,059,427||3,805,615|
|General funds||3,158,661|2,629,103|(1,155,306)|(2,025,494)|279,169|2,886,133|
|Restricted|funds|175,636|114,334|(34,420)|(33,933)||221,617|
|||5,479,948|2,743,437|(1,589,189)||279,169|6,913,365|



## 

## 

## 

|Analysis ofnet assets between funds -current year||||
|---|---|---|---|
||Unrestricted|Restricted|Total|
||funds|funds|funds|
||2021f|2021f|2021f|
|Tangible fixed assets|3,150||3,150|
|Fixed asset investments|7,759,251||7,759,251|
|Current assets|3,279,300|150,570|3,429,870|
|Creditors due within one year|(3,093,517)||(3,093,517)|
|Creditors due in more than one year|(1,272,321)||(1,272,321)|
|Total|6,675,863|150,570|6,826,433|



## 



## 

## 

|Analysis ofnet assets between|funds (continued)|||||
|---|---|---|---|---|---|
|Analysis ofnet assets between|funds - prior year|||||
|||Unrestricted||Restricted|Total|
||||funds|funds|funds|
||||2020<br>f|2020<br>6|2020f|
|Tangible fixed assets|||4,163||4,163|
|Intangible<br>fixed assets|||50,000||50,000|
|Fixed asset investments||5,837,650|||5,837,650|
|Current assets||4,286,023||221,617|4,507,640|
|Creditors due within<br>one year||(2,398,808)|||(2,398,808)|
|Creditors due in more than one year||(1,087,280)|||(1,087,280)|
|Total||6,691,748||221,617|6,913,365|
|Reconciliation<br>ofnet movement|in funds to net cash flow from operating||activities|||
|||||Group|Group|
|||||2021|2020|
|||||6|6|
|Net income/expenditure<br>for the|year (as per Statement of Financial Activities)|||(86,932)|1,433,417|
|Adjustments<br>for:||||||
|Depreciation<br>charges||||2,081|4,216|
|Impairment<br>charge||||50,000||
|Gains/(losses)<br>on investments||||332,141|(282,945)|
|Dividends<br>and interest from investments||||(154,257)|(165,194)|
|Loss on the sale offixed assets|||||53|
|Decrease in stocks|||||660|
|Decrease/(increase)<br>in debtors||||360,673|(71,493)|
|Increase/(decrease)<br>in creditors||||879,750|(768,528)|
|Net cash generated<br>hy openrting|activities|||1,384,050|150,186|



## 



## 

## 

## 

||Group|Group|
|---|---|---|
||2021|2020|
|||6|
|Cash in hand|246,297|144,427|
|Notice deposits (less than 3 months)|1,972,844|1,671,397|
|Total cash and cash equivalents|2,219,141|1,815,824|



## 


## 



## 

||Group|Group|
|---|---|---|
||2021|2020|
|||6|
|Group ond company|||
|Within 1year|65,521|63,271|
|Between 1and 5years|1,461|64,252|
||66,982|127,523|



|Group|Group|
|---|---|
|2021|2020|
|6||
|72,271|62,410|



## 



## 

## 

## 



## 

|NOTES TO THE FINANCIAL STATEMENTS|NOTES TO THE FINANCIAL STATEMENTS|NOTES TO THE FINANCIAL STATEMENTS|NOTES TO THE FINANCIAL STATEMENTS|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|FOR THE YEAR ENDED 31 DECEMBER 2021||||||||||||||
|Grants awarded 2021||||||||||||||
||||||||||||||2021|
|Medical Research and|Trustee Discretionary|||||Gnrnts||||||||
|Cambridge||||||||||||||
|University<br>ofCambridge||||||||||||||
|Prof Ziad Mallat||||||||||||||
|The effect of low-dose interleukin-2|||on human|||||atherosclerotic|plaque immune||cells at single cell|||
|resolution|||||||||||||191/76|
|Oxford||||||||||||||
|University<br>ofOxford||||||||||||||
|Prof Regent Lee||||||||||||||
|Using deep learning|methods to generate||||contrast enhanced||||computerised|tomography||||
|angiography<br>without|the use ofintravenous|||||contrast agents|||||||246,226|
|London||||||||||||||
|King's College London||||||||||||||
|Dr Nilesh Pareek||||||||||||||
|Developing<br>a digital handover<br>application<br>prehospital<br>stratification<br>for OOHCA -the|||||for paramedics to provide<br>a personalized<br> RAPID MIRACLE study|||||||approach to|248,110|
|King's College London||||||||||||||
|Prof Jaswinder<br>Gill||||||||||||||
|Sleep-disordered<br>breathing||and arrhythmias|||||(clinical)||||||87,000|
|Edinburgh||||||||||||||
|University<br>of Edinburgh||||||||||||||
|Prof Gillian Gray||||||||||||||
|Mass spectrometry<br>imaging||to illuminate||the|||activity of118-hydroxsteroid|||dehydrogenase||||
|1inhibitors<br>and their|potential for repurposing|||||||to prevent<br>heart failure development||||after||
|myocardi a I infa rcti on|||||||||||||88,568|
|Dundee||||||||||||||
|University<br>of Dundee||||||||||||||
|Prof Faisel Khan||||||||||||||
|Inflammatory<br>drivers|ofendothelial||dysfunction|||||in COVID-19|||||133,693|
|Glasgow||||||||||||||
|University<br>ofGlasgow||||||||||||||
|Prof Sandosh<br>Padmanabhan||||||||||||||
|Vascular effects ofSARS-COV-2 infection||||and|||long term impact on hypertension||||||250,000|
|University ofGlasgow||||||||||||||
|ProfJesse Dawson||||||||||||||
|Preventing<br>Recurrent<br>Study)|Cardioembolic||Stroke|||—New Blood Tests and Risk Prediction||||||(The PRECISE|115,811|
|Grants awarded 2021|corned|fonuard|||||||||||1,36020ut|





## 

|NOTES TO THE FINANCIAL|STATEMENTS|STATEMENTS|STATEMENTS|STATEMENTS|STATEMENTS|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|FOR THE YEAR ENDED 31 DECEMBER 2021||||||||||||||||
|Grants awarded 2021(continued)||||||||||||||||
||||||||||||||||2021|
||||||||||||||||E|
|Grants awarded 2021brought forward|||||||||||||||1,360,884|
|Manchester||||||||||||||||
|University of Manchester||||||||||||||||
|Dr Delvac Oceandy||||||||||||||||
|Pharmacological<br>inhibition<br>of||Hippo pathway||||forthe treatment||||ofadverse cardiac||||remodelling|151,203|
|Leeds||||||||||||||||
|Leeds Teaching Hospital|NHS Trust|||||||||||||||
|Ms Carin Van Doom||||||||||||||||
|Gerlis Heart Collection|||||||||||||||5,500|
|Bristol||||||||||||||||
|University of Bristol||||||||||||||||
|Prof Paolo Madeddu||||||||||||||||
|Targeting<br>pericytes for|halting||pulmonary<br>hypertension|||||in infants with congenital||||||heart disease|145,233|
|Newcastle||||||||||||||||
|Newcastle<br>University||||||||||||||||
|Prof Loakim Spyridopoulos||||||||||||||||
|Tcell immunity<br>and myocardial||||inflammation|||in patients|recovering|||from COVID-19 infection||||147,649|
|South Tees||||||||||||||||
|South Tees NHS Hospitals|Foundation|||||||||||||||
|Akowuah||||||||||||||||
|Pre-habilitation<br>in elderly patients|||||undergoing||cardiac surgery||||||||41,617|
|ulster||||||||||||||||
|Ulster University||||||||||||||||
|Escalona||||||||||||||||
|Minimal tissue heating|effects||technology for||||wireless energy|||supply to implanted||||ventricular||
|assist devices in the treatment||||ofheart failure|||||||||||1,000|
|London||||||||||||||||
|Kings College London||||||||||||||||
|Ellison-Hughes||||||||||||||||
|Targeting<br>cellular senescence as a therapy to <br>cardiomyocytes<br>and endothelial<br>cells|||||||rejuvenate|the|reparative|||activity|of|human|14,634|
|Glasgow||||||||||||||||
|University ofGlasgow||||||||||||||||
|Taylor||||||||||||||||
|implementation<br>ofan|evidence-based<br>cardiac||||||rehabilitation||home||programme||for heart failure||23,400|
|patients and their caregivers||in||Scotland: SCOTrREACH-H||||Fproject||||||||
|Grants awarded 2021carried forward|||||||||||||||1,891,120|





## 

## 

## 

## 







## 




## 



## 

|HRUK &Subway Healthy Heart Grants|2021(co|nti|nued)||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|||||||||||2021|
|HRUK &Subway Grants brought forward||||||||||94,493|
|Scotland|||||||||||
|Nutrition<br>Scotland|||||||||||
|Mrs Suzanne Fletcher|||||||||||
|Corkerhill<br>Healthy<br>Hearts Programme|-The Corkerhill|||Healthy|Hearts programme|||consists of|||
|cooking and nutrition<br>classes. Group members||will learn about a different|||||nutritional||topic each||
|week, culminating<br>in them cooking a heart healthy<br>meal together.||||||Digital resources|||will also be||
|created, expanding the reach ofthis project.||||||||||9,643|
|Northern<br>Ireland|||||||||||
|Newtownstewart<br>Leisure Complex<br>Ltd|||||||||||
|Mrs Irene Spratt|||||||||||
|Healthy<br>Hearts &Healthy<br>Minds - Community||Kitchen||Hub &Exercise - The Healthy|||||Hearts and||
|Minds project aims to actively reduce|the risk|of|heart|disease|in a deprived||area|of|||
|Newtownstewart<br>through<br>the delivery|ofhealthy||cooking and||physical activity sessions aimed at||||||
|both adults and children.||||||||||9,955|
|Harryville<br>Men's Shed|||||||||||
|Mr Denver McMeekin|||||||||||
|Harryville<br>Men's Walking<br>Football - The Haryville|||Men's Walking Football project|||||targets older|||
|men in Ballymena,<br>Northern<br>Ireland. This project|||aims|to get men||active through||a walking|||
|football and healthy<br>eating programme.||||||||||4,360|
|HRUK &Subway Grants awarded 2021||||||||||118,451|
|Grants written<br>back||||||||||(3,197)|
|Total HRUK &Subway Grants Awarded|2021|||||||||115,254|





## 

## 

|Subsidiary<br>name|Subsidiary<br>name|Subsidiary<br>name||Company|Basis of|Equity||
|---|---|---|---|---|---|---|---|
|||||number|control|shareholdlng||
|HRUK Helping||Hearts Limited||01562684|Direct||100%|
|The financial|results ofthe subsidiary||for the year were:|||||
|Name|||income|Expenditure|Profit/(Loss)|Net|assets|
|||||6|forthe year||E|
||||||E|||
|HRUK Helping||Hearts Limited|144,061|P4,919)|69,142|53,431||